Pay in 4 interest-free payments of $6.59 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Zepbound is an injectable GLP-1 receptor agonist approved by the FDA in 2023 for weight loss
USP is an independent scientific nonprofit organization that aims to help protect patient safety in medicines, dietary supplements, and foods worldwide
cost accumulates rapidly
The STEP 1 trial showed that participants receiving 2.4 mg weekly for 68 weeks lost an average of 14.9% of their body weight compared to 2.4% in the placebo group
There is also another medication, tirzepatide (brand names: Monjaro and Zepbound), which is a combination of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) agonists
US$ 21.82
US$ 24.44
US$ 27.61
US$ 23.87
US$ 20.33
US$ 23.93
US$ 26.71
